, 2013). In addition to the impact of circadian disturbances on disease, numerous studies in animal models and human clinical trials indicate that there is pronounced impact on the efficacy of a variety of treatments based on the timing of their delivery. Early work in rats and mice, for example, provided evidence that cancer chemotherapy was more efficacious if delivered at times of greatest drug tolerance (Halberg et al.,

1980; Levi, 1987; Reinberg et al., 1987). Later, it was recognized that cancer cells exhibit daily rhythms in mitotic activity, and cytotoxic chemotherapeutic agents could be most effectively applied during peak mitotic activity, ideally when cell division is at a nadir in

marrow and mucosal cells to avoid damage to healthy tissues (Ortiz-Tudela et al., 2013). Despite repeated clinical TSA HDAC trials for a number of cancers revealing enormous increases in response rate and survivorship and decreased negative side-effects, it has been challenging to incorporate a chronotherapeutic strategy into oncological practice. Part of the challenge arises from the fact that sex, lifestyle, and genetic background influence the most appropriate time of delivery across individuals (Ortiz-Tudela et al., 2013). The finding of high-throughput, reliable circadian biomarkers for host and cancerous tissues, along with the implementation of timed drug-delivery systems, is currently being explored to bring chronotherapeutic approaches to the clinic. More recently, it has become clear that vast improvements in the efficacy of pharmacological, GSK J4 in addition Teicoplanin to chemotherapeutic, agents can be gained by considering the timing of delivery. One strategy that has met with success is to administer

medication at a time of greatest risk (e.g. myocardial infarction risk is greatest in the morning) or at the daily peak in the manifestation of the ailment (e.g. asthma symptoms exhibit marked daily changes) (Bairy, 2013). A more effective strategy is to consider daily changes in drug pharmacodynamics and to deliver medications at a time when the drug is best tolerated and metabolism and elimination are lowest. For over 300 drugs, prominent daily changes in absorption, distribution, metabolism, and elimination have been noted (reviewed in Levi & Schibler, 2007). By considering these daily changes in pharmacokinetics, striking increases in plasma concentrations of a drug can be achieved simply by altering the timing of administration (e.g. Ollagnier et al., 1987; Smolensky et al., 1987; Bruguerolle, 1998) (Fig. 5). In addition to maximizing the concentration of drugs and minimizing their toxicity, drug targets exhibit daily changes that alter the response, including erythrocyte permeability (Levi et al., 1987; Bruguerolle & Prat, 1989) and receptor numbers/binding affinity (Redfern, 2003).